Description

IDEXX Lab’s Next Big Catalyst — Cancer Dx, inVue Dx & A Broader Testing Menu!

IDEXX Laboratories reported solid financial results for the second quarter of 2026, continuing revenue growth driven primarily by its Companion Animal Group (CAG) Diagnostics segment. Total revenue increased approximately 10% as reported and 9% organically, led by over 10% organic growth in CAG Diagnostics recurring revenues. Growth was complemented by double-digit gains in both domestic and international markets, strong performances in the Water and Livestock, Poultry and Dairy (LPD) businesses, and ongoing expansion in software and diagnostic imaging. The company’s recurring revenue streams benefited from expanded test volumes and effective pricing strategies, with a global net price improvement near 4%. However, U.S. same-store clinical visits declined by an estimated 1.3%, primarily driven by a 3.4% decrease in wellness visits, reflecting broader consumer discretionary pressure and muted new pet adoption trends.